http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
백우현,기훈재,유장식,이상원,김수원,Paik, Woo-Hyun,Ki, Hoon-Jae,Yoo, Jang-Sik,Lee, Sang-Won,Kim, Soo-Won 대한전자공학회 1999 電子工學會論文誌, D Vol.d36 No.1
본 논문에서는 저전력/고속 디지털 FIR 필터를 위한 새로운 파이프라인 구조를 제안한다. 제안된 파이프 라인 구조는 입력 데이터와 계수간 곱셈의 일부를 입력 지연단에서 수행하도록 하는 리타이밍 기법을 사용하여 속도를 향상시켰으며 공급전압을 낮추는 방법을 병행하여 전력을 감소시켰다. 제안된 파이프라인 구조를 적용하여 PRML 디스크 드라이브용 8 탭 FIR 필터를 설계하고 0.8${\mu}m$ CMOS 공정을 이용하여 제작하였다. 실험결과 설계된 FIR 필터는 3.3.V에서 최대 192 MHz까지 동작하였으며 이 때 1.22 mW/MHz의 전력을 소모하였다. 결과적으로 제안된 구조의 FIR 필터는 기존의 구조에 비해 약 16%의 속도가 향상되었으며 같은 데이터 처리능력을 가질 때 약 23%의 전력 감소 효과를 갖는다. This paper presents new pipeline architecure for low power and high speed digital FIR filters. The proposed architecture based on retiming technique achieves enhancement on speed by sharing the input delay stage with multiplication of input data and on power combined with supply voltage scaling down technique. An 8-tap digital FIR filter for PRML disk-drive read channels adopting the proposed pipeline architecture has been designed and fabricated with 0.8${\mu}m$ CMOS double metal process technology. Measured results show that the designed FIR filter operates to 192 MHz in average and dissipates 1.22 mW/MHz at 3.3.V power supply. As a result, the proposed architecture improves speed by about 16% and reduces power dissipation by about 23% when operating at the same throughput.
나프록센의 Alkanol 에스테르류에 관한 생물약제학적 연구 I - 3종의 Alkanol 에스테르의 합성 -
백우현(Woo Hyun Paik),김종갑(Johng Kap Kim) 대한약학회 1986 약학회지 Vol.30 No.3
Three new alkanol esters of d-2-(6-methoxy-2-naphthyl)propionic acid, NAPROXEN were synthesized by esterification of sodium naproxen with chloralcohols, such as 2-chloroethanol, 3-chloro-1, 2-propanediol and beta-chloroethoxyethanol in dimethylformamide. These new esters were obtained with comparably high yield and identified by elemental analysis, UV, IR and NMR techniques.
췌장암에 대한 예후 생물표지자로서의 MicroRNA-200c
백우현 ( Woo Hyun Paik ),송병준 ( Byeong Jun Song ),김형우 ( Hyoung Woo Kim ),김혜리 ( Hye Ree Kim ),황진혁 ( Jin Hyeok Hwang ) 대한소화기학회 2015 대한소화기학회지 Vol.66 No.4
Background/Aims: MicroRNA (miRNA) regulates messenger RNA stability and translation. In cancer biology, miRNA affects the growth and metastasis of cancer cells by controlling epithelial-mesenchymal transition (EMT). MiR-200 family (200a/200b/ 200c/141) and miR-205 are associated with the regulation of EMT. We investigated the prognostic role of EMT-related miRNAs in pancreatic cancer. Methods: We analyzed miR-200 family and miR-205 expression in tissue samples of 84 patients who underwent radical resection for pancreatic cancer. Results: Patients were followed from the date of diagnosis until death or censoring. The mean overall survival was 25.0±2.0 months (2-140 months). The R0 resection rate was obtained in 84.5% (n=71) of patients. The relative expressions of miR-200a/200b/200c/141 and miR-205 were 266.9±57.3/18.5±2.2/0.7±0.1/27.2±6.6 folds and 0.1±0.1 compared with human pancreatic ductal epithelial cells, respectively. Overall survival was longer in the low miR-200c expression group than in the high expression group (35 vs. 19 months, p=0.013). Multivariate analysis confirmed that patients with low miR-200c expression survived longer than the high expression group (hazard ratio, 1.771, 95% CI, 1.081-2.900, p=0.023). There was a trend toward longer disease-free survival in low miR-200c group without statistical significance (p=0.061). Conclusions: The expression of miR-200c may be an important prognosis factor in pancreatic cancer, and it could be a novel therapeutic target of pancreatic cancer. (Korean J Gastroenterol 2015,66:215-220)
백우현 ( Woo Hyun Paik ),장동기 ( Dong Kee Jang ),이준규 ( Jun Kyu Lee ) 대한췌담도학회 2018 대한췌담도학회지 Vol.23 No.2
췌장염 환자의 10-30%는 그 원인을 찾지 못하여 특발성 췌장염으로 분류되며, 그중 일부는 유전적 변이가 원인일 것으로 생각된다. 유전성 췌장염은 소아 때부터 췌장염 관련 증상이 발생하여 대부분 30대 전후로 만성 췌장염으로 진행하기 때문에 췌장암의 발생에 대해 각별한 주의가 필요하다. 췌장염 관련 유전자는 현재까지 30종류 이상 발견되었으며, 대표적으로 PRSS1, SPINK1, CFTR, CTRC 변이가 있으며, 이는 인종 및 지역에 따라 다양성을 보이고 있다. 따라서, 국내특발성 췌장염 환자를 대상으로 한 유전자 연구를 통하여 한국인에서의 췌장염 관련 유전자 변이의 양상 및 특징을 파악하는 것이 중요하겠다. 본고에서는 특발성 췌장염의 병태생리에서 유전적 변이의 역할에 대해 중점적으로 고찰해보고, 국내 문헌을 토대로 특발성 혹은 유전성 췌장염의 국내 연구결과를 살펴보고자 한다. 10-30% of patients with pancreatitis can be categorized as idiopathic pancreatitis, and some of them may be due to genetic alterations. Since hereditary pancreatitis develops from pediatric patients with symptoms related to pancreatitis, which usually progresses to chronic pancreatitis around 30 years of age, special attention should be paid to the development of pancreatic cancer in such patients. Up to now, there have been more than 30 genetic alterations associated with pancreatitis. Alterations in protease serine 1 (PRSS1), serine protease inhibitor Kazal type 1 (SPINK1), cystic fibrosis transmembrane conductance regulator (CFTR) and chymotrypsin C (CTRC) are common, which show diversity according to race and region. It is important to understand the characteristics of Korean patients with idiopathic pancreatitis through genetic studies. The purpose of this article is to review the role of genetic variations in the pathophysiology of idiopathic pancreatitis and to survey the results of Korean studies of idiopathic pancreatitis.
백우현(Woo-Hyun Paik) 大韓藥學會 2015 약학회지 Vol.59 No.1
The term "GMP” firstly came on the 1962 amendment of the Federal Food, Drug and Cosmetic (FD&C) Act and the US FDA established and officially announced the Good Manufacturing Practice Regulation for the first time in the world in 1963. In 1969, the World Health Organization published the GMP regulation and recommended that member states adopt the GMP regulation and implement the "GMP Certification Scheme” for international commerce of finished pharmaceutical products. As a result, GMP requirements have become important ones that have to be complied with in the manufacture of pharmaceutical products. The Korean GMP regulation was announced as the official notification by the Ministry of Health and Social Affairs in 1977. The KGMP regulation was voluntarily adopted by pharmaceutical companies at the early stage, but it had become mandatory. In addition, various kinds of GMP regulations have been established to cover active pharmaceutical ingredients, biological products and others, in addition to finished pharmaceutical products. Taking account of technological development and changes in the pharmaceutical environments, the KGMP regulation was fully amended and harmonized with GMP requirements of developed countries. In this way, the KGMP has developed to keep up with international trends and standards, leading to accession to the Pharmaceutical Inspection Cooperation Scheme (PIC/S).
백우현 ( Woo Hyun Paik ),윤용범 ( Yong Bum Yoon ),이상협 ( Sang Hyub Lee ),박주경 ( Joo Kyung Park ),우상명 ( Sang Myung Woo ),양기영 ( Ki Young Yang ),서정균 ( Jeong Kyun Seo ),류지곤 ( Ji Kon Ryu ),김용태 ( Yong Tae Kim ) 대한소화기학회 2008 대한소화기학회지 Vol.52 No.3
Background/Aims: Since pancreatic endocrine tumors (PET) are rare and heterogeneous diseases, their survival and prognosis are not well known. Due to recent advances in CT/MRI technology, incidentalomas of the pancreas are detected with increasing frequency. This study presents results of clinical manifestations of PET and predictive factors associated with survival. Methods: From year 1990 through 2006, medical records of 98 patients (56 men, 42 women) who were diagnosed as PET pathologically at Seoul National University Hospital were reviewed retrospectively. Results: Ages ranged from 17 to 76 years (mean 51.6±1.3 years) with a mean follow-up of 3.6±0.4 years (range 0-10.1 years). Overall 5-year survival rate was 68.1%, and 5-year survival rate of the patients who had distant metastases at initial diagnosis was 43.9%. Functioning tumors [hazard ratio (HR) 0.229, 95% confidence interval (CI) 0.056-0.943, p=0.041] and lymph node or liver metastases (HR 5.537, 95% CI 2.106-14.555, p<0.001) were the significant prognostic factors associated with survival rate. However, tumor size and pathology showed no significant association with survival. Conclusions: Because small and pathologically benign nature do not predict good prognosis in PET, aggressive treatment such as curative resection would be considered initially even in the case of incidental PET. (Korean J Gastroenterol 2008;52:171-178)